Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Najít Technologies Inc. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner in 1 distinct art unit. This reflects a singular and focused point of examination for the company's current patent applications. For a practitioner, this means that the entire prosecution strategy is focused on the standards of a single art unit and the specific expectations of one examiner.
ZOU, NIANXIANG is the busiest examiner for the portfolio, responsible for 1 pending office action. This examiner handles the entirety of the company's pending action. The presence of 1 distinct art unit for this action indicates that the biotechnology technology is being evaluated within a single specialized group. This structure allows for a highly focused dialogue between the practitioner and the examiner, as there are no other pending matters or examiners to coordinate with at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZOU, NIANXIANG | 1 | 64.1% | +24.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292873 | MULTIVALENT PAN-INFLUENZA VACCINE | ZOU, NIANXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292873 | MULTIVALENT PAN-INFLUENZA VACCINE | ZOU, NIANXIANG | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18292873 | MULTIVALENT PAN-INFLUENZA VACCINE | ZOU, NIANXIANG | 1671 | §101§103 | Non-Final OA | — | Pending | Jan 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial